Lawrence J. Jennings, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Aparna Kalyan, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Lawrence J. Jennings, MD, PhD

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.

Aparna Kalyan, MD 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor 
Boston Scientific Corporation: Consulting Fee; Honoraria; Scientific Advisor
Exelixis Inc.: Consulting Fee; Honoraria; Scientific Advisor
Genentech, Inc.: Consulting Fee; Honoraria; Scientific Advisor
QED Therapeutics, Inc.: Consulting Fee; Scientific Advisor

Congress Co-Moderators

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.  

Anthony J. Olszanski, MD, RPh  
Bristol-Myers Squibb Company: Scientific Advisor 
Eisai Inc.: Scientific Advisor  
InstilBio: Scientific Advisor  
Merck & Co., Inc.: Scientific Advisor  
Nektar Therapeutics: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Oncosec Immunotherapies: Scientific Advisor 
Pfizer Inc.: Honoraria 
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor 

Tuya Pal, MD 
Natera, Inc.: Scientific Advisor 

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

Crystal S. Denlinger, MD 
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support 
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor 
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor 
Zymeworks: Scientific Advisor; Grant/Research Support 

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.